Overview of the Interplay Between M6A Methylation Modification and Non-coding RNA and Their Impact on Tumor Cells

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Jul 11

PMID 38988908

Authors

Zheng Dou

Xiao-Ting Ma

Mei-Na Piao

Jian-Ping Wang

Jin-Li Li

Affiliations

Soon will be listed here.

Abstract

N6-methyladenosine (m6A) is one of the most common internal modifications in eukaryotic RNA. The presence of m6A on transcripts can affect a series of fundamental cellular processes, including mRNA splicing, nuclear transportation, stability, and translation. The m6A modification is introduced by m6A methyltransferases (writers), removed by demethylases (erasers), and recognized by m6A-binding proteins (readers). Current research has demonstrated that m6A methylation is involved in the regulation of malignant phenotypes in tumors by controlling the expression of cancer-related genes. Non-coding RNAs (ncRNAs) are a diverse group of RNA molecules that do not encode proteins and are widely present in the human genome. This group includes microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and PIWI interaction RNAs (piRNAs). They function as oncogenes or tumor suppressors through various mechanisms, regulating the initiation and progression of cancer. Previous studies on m6A primarily focused on coding RNAs, but recent discoveries have revealed the significant regulatory role of m6A in ncRNAs. Simultaneously, ncRNAs also exert their influence by modulating the stability, splicing, translation, and other biological processes of m6A-related enzymes. The interplay between m6A and ncRNAs collectively contributes to the occurrence and progression of malignant tumors in humans. This review provides an overview of the interactions between m6A regulatory factors and ncRNAs and their impact on tumors.

References

Shen J, Feng X, Hu R, Wang H, Wang Y, Qian J . N-methyladenosine reader YTHDF2-mediated long noncoding RNA FENDRR degradation promotes cell proliferation in endometrioid endometrial carcinoma. Lab Invest. 2021; 101(6):775-784. DOI: 10.1038/s41374-021-00543-3. View

Fang D, Ou X, Sun K, Zhou X, Li Y, Shi P . m6A modification-mediated lncRNA TP53TG1 inhibits gastric cancer progression by regulating CIP2A stability. Cancer Sci. 2022; 113(12):4135-4150. PMC: 9746054. DOI: 10.1111/cas.15581. View

Liu P, Fan B, Othmane B, Hu J, Li H, Cui Y . mA-induced lncDBET promotes the malignant progression of bladder cancer through FABP5-mediated lipid metabolism. Theranostics. 2022; 12(14):6291-6307. PMC: 9475447. DOI: 10.7150/thno.71456. View

Gu Y, Niu S, Wang Y, Duan L, Pan Y, Tong Z . -Mediated Regulation of mA-Modified by mA Reader IGF2BP3 Drives ccRCC Progression. Cancer Res. 2020; 81(4):923-934. DOI: 10.1158/0008-5472.CAN-20-1619. View

Ren Z, Hu Y, Sun J, Kang Y, Li G, Zhao H . N-methyladenosine methyltransferase WTAP-stabilized FOXD2-AS1 promotes the osteosarcoma progression through mA/FOXM1 axis. Bioengineered. 2022; 13(4):7963-7973. PMC: 9161975. DOI: 10.1080/21655979.2021.2008218. View

Wang J, Ding W, Xu Y, Tao E, Mo M, Xu W . Long non-coding RNA RHPN1-AS1 promotes tumorigenesis and metastasis of ovarian cancer by acting as a ceRNA against miR-596 and upregulating LETM1. Aging (Albany NY). 2020; 12(5):4558-4572. PMC: 7093190. DOI: 10.18632/aging.102911. View

Wang S, Wang Y, Zhang Z, Zhu C, Wang C, Yu F . Long Non-Coding RNA NRON promotes Tumor Proliferation by regulating ALKBH5 and Nanog in Gastric Cancer. J Cancer. 2021; 12(22):6861-6872. PMC: 8518016. DOI: 10.7150/jca.60737. View

Shan L, Lu Y, Xiang C, Zhu X, Zuo E, Cheng X . Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database. J Immunol Res. 2022; 2022:2547029. PMC: 9095403. DOI: 10.1155/2022/2547029. View

Wang W, Dong D, Yu P, Chen T, Gao R, Wei J . Prognostic model based on m6A-associated lncRNAs in esophageal cancer. Front Endocrinol (Lausanne). 2022; 13:947708. PMC: 9468245. DOI: 10.3389/fendo.2022.947708. View

10.

Chen J, Tao Y, Hong Y, Li H, Huang Z, Xu X . MA-mediated up-regulation of LncRNA LIFR-AS1 enhances the progression of pancreatic cancer via miRNA-150-5p/ VEGFA/Akt signaling. Cell Cycle. 2021; 20(23):2507-2518. PMC: 8794522. DOI: 10.1080/15384101.2021.1991122. View

11.

Cai J, Chen Z, Zhang Y, Wang J, Zhang Z, Wu J . CircRHBDD1 augments metabolic rewiring and restricts immunotherapy efficacy via mA modification in hepatocellular carcinoma. Mol Ther Oncolytics. 2022; 24:755-771. PMC: 8908059. DOI: 10.1016/j.omto.2022.02.021. View

12.

Zhang L, Ke W, Hu P, Li Z, Geng W, Guo Y . N6-Methyladenosine-Related lncRNAs Are Novel Prognostic Markers and Predict the Immune Landscape in Acute Myeloid Leukemia. Front Genet. 2022; 13:804614. PMC: 9125310. DOI: 10.3389/fgene.2022.804614. View

13.

Liu L, Gu M, Ma J, Wang Y, Li M, Wang H . CircGPR137B/miR-4739/FTO feedback loop suppresses tumorigenesis and metastasis of hepatocellular carcinoma. Mol Cancer. 2022; 21(1):149. PMC: 9297645. DOI: 10.1186/s12943-022-01619-4. View

14.

Yao B, Zhang Q, Yang Z, An F, Nie H, Wang H . CircEZH2/miR-133b/IGF2BP2 aggravates colorectal cancer progression via enhancing the stability of mA-modified CREB1 mRNA. Mol Cancer. 2022; 21(1):140. PMC: 9245290. DOI: 10.1186/s12943-022-01608-7. View

15.

Liang L, Zhu Y, Li J, Zeng J, Wu L . ALKBH5-mediated m6A modification of circCCDC134 facilitates cervical cancer metastasis by enhancing HIF1A transcription. J Exp Clin Cancer Res. 2022; 41(1):261. PMC: 9413927. DOI: 10.1186/s13046-022-02462-7. View

16.

Wu Q, Zhang H, Yang D, Min Q, Wang Y, Zhang W . The m6A-induced lncRNA CASC8 promotes proliferation and chemoresistance via upregulation of hnRNPL in esophageal squamous cell carcinoma. Int J Biol Sci. 2022; 18(13):4824-4836. PMC: 9379415. DOI: 10.7150/ijbs.71234. View

17.

Feng Z, Liang Y, Cen J, Yao H, Lin H, Li J . m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer. J Transl Med. 2022; 20(1):492. PMC: 9617388. DOI: 10.1186/s12967-022-03711-1. View

18.

Sun L, Wan A, Zhou Z, Chen D, Liang H, Liu C . RNA-binding protein RALY reprogrammes mitochondrial metabolism via mediating miRNA processing in colorectal cancer. Gut. 2020; 70(9):1698-1712. PMC: 8355885. DOI: 10.1136/gutjnl-2020-320652. View

19.

Kong H, Sun J, Zhang W, Zhang H, Li H . Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3. Bioengineered. 2022; 13(2):3108-3121. PMC: 8973700. DOI: 10.1080/21655979.2022.2025701. View

20.

Hosono Y, Niknafs Y, Prensner J, Iyer M, Dhanasekaran S, Mehra R . Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. Cell. 2017; 171(7):1559-1572.e20. PMC: 5734106. DOI: 10.1016/j.cell.2017.11.040. View